Inflammation in renal transplantation

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 7, 2009, Pages 1246-1254

  Abedini, Sadollah ^a   Holme, Ingar ^b   März, Winfried ^c   Weihrauch, Gisela ^d   Fellström, Bengt ^e   Jardine, Alan ^f   Cole, Edward ^g   Maes, Bart ^h   Neumayer, Hans Hellmut ⁱ   Grønhagen Riska, Carola ^j   Ambühl, Patrice ^k   Holdaas, Hallvard ^l  

^a Toensberg County Hospital   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c SYNLAB ACADEMY   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f WESTERN INFIRMARY   (United Kingdom)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h Heilig Hartziekenhuis   (Belgium)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FLUINDOSTATIN; INTERLEUKIN 6; PLACEBO; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT RECIPIENT; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN STUDY; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; BLOOD; CHRONIC KIDNEY FAILURE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 70349316911     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00930209     Document Type: Article

References (47)

1. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031, 2003
2. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG: Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 5: 2929-2936, 2005
3. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735-1743, 2000
4. Rigatto C, Parfrey P: Therapy insight: Management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol 2: 514-526, 2006
5. Kaysen GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 12: 1549-1557, 2001
6. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 109: II2-II10, 2004
7. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005
8. Vazquez MA, Jeyarajah DR, Kielar ML, Lu CY: Long-term outcomes of renal transplantation: A result of the original endowment of the donor kidney and the inflammatory response to both alloantigens and injury. Curr Opin Nephrol Hypertens 9: 643-648, 2000
9. Cottone S, Palermo A, Vaccaro F, Mule G, Guarneri M, Arsena R, Vadala A, Cerasola G: Inflammation and endo-thelial activation are linked to renal function in long-term kidney transplantation. Transpl Int 20: 82-87, 2007
10. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH: Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114: 2047-2055, 2006
11. Martinez-Castelao A, Sarrias X, Bestard O, Gil-Vernet S, Seron D, Cruzado JM, Moreso F, Diez-Noguera A, Grinyo JM: Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. Transplant Proc 37: 3788-3790, 2005
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979, 1997
13. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610, 2004
14. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Mac-Fadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008
15. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
16. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int 61: S99-S102. 2002
17. Lauzurica R, Pastor MC, Bayes B, Hernandez JM, Bonet J, Dolade M, Navarro M, Romero R: Pretransplant inflammation: A risk factor for delayed graft function? J Nephrol 21: 221-228, 2008
18. Mange KC, Joffe MM, Feldman HI: Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 344: 726-731, 2001
19. Bakri RS, Afzali B, Covic A, Sriskantharan R, Bharma-Ariza P, Park WH, Sriharan M, Dalton N, Wierzbicki AS, Crook MA, Goldsmith DJ: Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant 18: 201-204, 2004
20. Varagunam M, Finney H, Trevitt R, Sharples E, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM: Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis 43: 502-507, 2004
21. Ducloux D, Kazory A, Chalopin JM: Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 66: 441-447, 2004
22. Winkelmayer WC, Lorenz M, Kramar R, Fodinger M, Horl WH, Sunder-Plassmann G: C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant 4: 1148-1154, 2004
23. Winkelmayer WC, Schaeffner ES, Chandraker A, Kramar R, Rumpold H, Sunder-Plassmann G, Fodinger M: A Jshaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. Transpl Int 20: 505-511, 2007
24. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 18: 387-394, 1998
25. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int 61: S103-S108, 2002
26. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999
27. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002
28. Kruger B, Boger CA, Schroppel B, Farkas S, Schnitzbauer AA, Hoffmann U, Obed A, Murphy BT, Banas B, Kramer BK: No effect of C-reactive protein (CRP) haplotypes on CRP levels and post-transplant morbidity and mortality in renal transplantation. Transpl Int 21: 452-458, 2008
29. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG: Genetically Elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897-1908, 2008
30. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey SG: C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366: 1954-1959, 2005
31. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511, 2003
32. Kusec V, Smalcelj R, Puretic Z, Szekeres T: Interleukin-6, transforming growth factor-beta 1, and bone markers after kidney transplantation. Calcif Tissue Int 75: 1-6, 2004
33. Ioannidou E, Kao D, Chang N, Burleson J, Dongari-Bagtzoglou A: Elevated serum interleukin-6 (IL-6) in solidorgan transplant recipients is positively associated with tissue destruction and IL-6 gene expression in the periodontium. J Periodontol 77: 1871-1878, 2006
34. Sezer S, Akcay A, Ozdemir FN, Kulah E, Arat Z, Haberal M: Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant 18: 722-725, 2004
35. van Ree RM, Oterdoom LH, de Vries AP, Gansevoort RT, van der Heide JJ, van Son WJ, Ploeg RJ, de Jong PE, Gans RO, Bakker SJ: Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients. Nephrol Dial Transplant 22: 246-253, 2007
36. Cueto-Manzano AM, Morales-Buenrostro LE, Gonzalez-Espinoza L, Gonzalez-Tableros N, Martin-del-Campo F, Correa-Rotter R, Valera I, Alberu J: Markers of inflammation before and after renal transplantation. Transplantation 80: 47-51, 2005
37. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 79: 914-919, 2005
38. Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109: 1955-1959, 2004
39. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106: 506-512, 1999
40. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 107-114, 1998
41. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972-978, 1999
42. Lowrie EG, Lew NL: Commonly measured laboratory variables in hemodialysis patients: Relationships among them and to death risk. Semin Nephrol 12: 276-283, 1992
43. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451-459, 2004
44. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
45. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
46. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74: 1461-1467, 2008
47. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease-Major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60: 451-457, 1995